SCHEMBL3487230

SCHEMBL3487230

CC(C)(CO)c1ccc(C(=O)Nc2cn3cc(-c4cn[nH]c4)ccc3n2)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 11/20 0.82
CLK2 P49760 8/20 0.80
CLK1 P49759 4/20 0.80
HRH1 P35367 2/20 0.49
PDGFRB P09619 1/20 0.49
KIT P10721 1/20 0.49
PDGFRA P16234 1/20 0.49
FLT3 P36888 1/20 0.49
CLK3 P49761 1/20 0.49
DYRK1A Q13627 1/20 0.49
SIK2 Q9H0K1 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
DYRK1B Q9Y463 1/20 0.49
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49
CHRM1 P11229 1/20 0.49
DRD2 P14416 1/20 0.49
ADRA2B P18089 1/20 0.49
DRD1 P21728 1/20 0.49
HRH2 P25021 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3486166 0.90 MAP3K5 (1.00) MAP3K5CLK2CLK1HRH1PDGFRB
SCHEMBL3485554 0.87 MAP3K5 (0.83) MAP3K5CLK2CLK1HRH1PDGFRB
SCHEMBL3486027 0.86 MAP3K5 (0.82) MAP3K5CLK2CLK1HRH1PDGFRB
SCHEMBL3486459 0.83 MAP3K5 (0.59) MAP3K5CLK2CLK1HRH1PDGFRB
SCHEMBL3486151 0.83 CLK2 (1.00) MAP3K5CLK2CLK1HRH1PDGFRB
Hydrochloric Acid SCHEMBL3486671 0.83 MAP3K5 (0.58) MAP3K5CLK2CLK1HRH1PDGFRB
SCHEMBL3485677 0.82 MAP3K5 (0.61) MAP3K5CLK2CLK1HRH1PDGFRB
SCHEMBL3487503 0.82 MAP3K5 (0.77) MAP3K5CLK2CLK1HRH1PDGFRB
SCHEMBL3487163 0.79 CLK2 (0.67) MAP3K5CLK2CLK1
SCHEMBL3486443 0.79 MAP3K5 (0.79) MAP3K5CLK2CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4582100-A1 MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER Toray Industries, Inc. (JP) 2025-07-09 EP disclosed
CN-119789868-A Medicine for treating and/or preventing cancer 东丽株式会社 2025-04-08 CN disclosed
WO-2024048541-A1 MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER 東レ株式会社 2024-03-07 WO disclosed
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 EP disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND IRAK1, IL1R1, IRAK2 MAP3K5 42/4885CLK2 2521/4885CLK1 2385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.